ECT2 anticorps (AA 781-883)

N° du produit ABIN753853

Détail du produit anti-ECT2 anticorps

Antigène: ECT2 (Epithelial Cell Transforming Sequence 2 Oncogene (ECT2))

Épitope: AA 781-883

Reactivité: Humain, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ECT2 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Humain, Rat

Homologie: Mouse,Dog,Cow,Chicken,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human ECT2

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-ECT2 (ABIN753853)

Wang, Yan, Liu: "Clinical significance of ECT2 expression in tissue and serum of gastric cancer patients." dans: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, Vol. 18, Issue 7, pp. 735-42, (2016) (PubMed).

Guo, Chen, Du, Zhu, Lai, Dong, Wu, Lin, Liu, Huang: "Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer." dans: Medical oncology (Northwood, London, England), Vol. 34, Issue 1, pp. 13, (2016) (PubMed).

Détails sur ECT2

Antigène: ECT2 (Epithelial Cell Transforming Sequence 2 Oncogene (ECT2))

Autre désignation: ECT2 (ECT2 Produits)

Synonymes: anticorps ECT2, anticorps arhgef31, anticorps xect2, anticorps AI528536, anticorps mKIAA4037, anticorps ARHGEF31, anticorps ect2, anticorps epithelial cell transforming 2, anticorps ect2 oncogene, anticorps epithelial cell transforming 2 S homeolog, anticorps ECT2, anticorps ect2, anticorps Ect2, anticorps ect2.S

Sujet:

Synonyms: ARHGEF31, Protein ECT2, Epithelial cell-transforming sequence 2 oncogene, ECT2

Background: Guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP. Promotes guanine nucleotide exchange on the Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. Required for signal transduction pathways involved in the regulation of cytokinesis. Component of the centralspindlin complex that serves as a microtubule-dependent and Rho-mediated signaling required for the myosin contractile ring formation during the cell cycle cytokinesis. Regulates the translocation of RHOA from the central spindle to the equatorial region. Plays a role in the control of mitotic spindle assembly, regulates the activation of CDC42 in metaphase for the process of spindle fibers attachment to kinetochores before chromosome congression. Involved in the regulation of epithelial cell polarity, participates in the formation of epithelial tight junctions in a polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. Plays a role in the regulation of neurite outgrowth. Inhibits phenobarbital (PB)-induced NR1I3 nuclear translocation. Stimulates the activity of RAC1 through its association with the oncogenic PARD6A-PRKCI complex in cancer cells, thereby acting to coordinately drive tumor cell proliferation and invasion. Also stimulates genotoxic stress-induced RHOB activity in breast cancer cells leading to their cell death.

ID gène: 1894

UniProt: Q9H8V3

Pathways: Neurotrophin Signaling Pathway, Cell-Cell Junction Organization